Cosmo N.V. has reported significant growth in recurring revenues for the first half of 2026, driven by strong performances from its key products and advancements in its clinical pipeline.
The company achieved a notable 38% increase in revenue from Winlevi® and a 35% rise from Lialda®, alongside a 14% growth in its Contract Development and Manufacturing Organization (CDMO) segment. This growth underscores the strength and diversification of Cosmo's business model. Furthermore, the Phase III clinical trial for Clascoterone 5% topical solution yielded positive data supporting its use for chronic conditions, with regulatory submissions planned for both the U.S. and Europe in 2027.
Cosmo's financial position remains robust, ending the reporting period with over €205 million in cash and no debt, providing a solid foundation for future investments in its pipeline and technology platforms. The company anticipates continued double-digit growth in its GI Genius™ platform and expects to maintain its full-year guidance of €105-110 million in total revenues.
Looking ahead, Cosmo's strategic focus on expanding its dermatology and gastrointestinal pipelines, alongside advancements in its AI-driven technologies, positions it well for sustained growth. The upcoming regulatory submissions and ongoing clinical trials could further enhance its market presence and product offerings in the evolving life sciences landscape.